Literature DB >> 8054448

Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease.

R Sutton1, M E Keohane, S R VanderBerg, S L Gonias.   

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is a serpin proteinase inhibitor which regulates fibrinolysis and the proteinase cascade of tumour invasion. In this study, PAI-1 was identified in the cerebrospinal fluid (CSF) from patients without neurological disease and patients with various neurological disorders. The mean level of PAI-1 in the CSF of 28 patients without central nervous system (CNS) disease was 0.28 +/- 0.03 (SEM) ng/ml. CSF PAI-1 was significantly increased in the following diagnostic categories:dementia (Alzheimer's disease), cerebral infarction, CNS infection, alcohol withdrawal seizures and CNS neoplasia. In all these disorders, with the exception of CNS infection, PAI-1 was also increased as a fraction of total CSF protein. CSF PAI-1 was not increased in patients with hydrocephalus or idiopathic seizure disorders. Complementary plasma samples were available for 18 of the 128 CSF specimens studied. For these cases, there was no correlation between plasma PAI-1 and CSF PAI-1 levels. PAI-1 may represent a non-specific marker of disease in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8054448     DOI: 10.1097/00001721-199404000-00002

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  18 in total

1.  Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer's disease.

Authors:  R-M Liu; T van Groen; A Katre; D Cao; I Kadisha; C Ballinger; L Wang; S L Carroll; L Li
Journal:  Neurobiol Aging       Date:  2009-07-14       Impact factor: 4.673

2.  Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease.

Authors:  Kwang Soo Kim; Yu Ree Choi; Ji-Young Park; Jung-Ho Lee; Dong Kyu Kim; Seung-Jae Lee; Seung R Paik; Ilo Jou; Sang Myun Park
Journal:  J Biol Chem       Date:  2012-05-22       Impact factor: 5.157

Review 3.  Tissue plasminogen activator in central nervous system physiology and pathology.

Authors:  Jerry P Melchor; Sidney Strickland
Journal:  Thromb Haemost       Date:  2005-04       Impact factor: 5.249

4.  Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease.

Authors:  F O Akenami; M Koskiniemi; M Färkkilä; A Vaheri
Journal:  J Clin Pathol       Date:  1997-02       Impact factor: 3.411

5.  Expression and localization of Inter-alpha Inhibitors in rodent brain.

Authors:  X Chen; L Rivard; S Naqvi; S Nakada; J F Padbury; J Sanchez-Esteban; E G Stopa; Y-P Lim; B S Stonestreet
Journal:  Neuroscience       Date:  2016-03-08       Impact factor: 3.590

6.  The plasmin system is induced by and degrades amyloid-beta aggregates.

Authors:  H M Tucker; M Kihiko; J N Caldwell; S Wright; T Kawarabayashi; D Price; D Walker; S Scheff; J P McGillis; R E Rydel; S Estus
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

7.  Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases.

Authors:  F O Akenami; V Sirén; M Koskiniemi; M A Siimes; H Teräväinen; A Vaheri
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

Review 8.  Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease.

Authors:  Sang Myun Park; Kwang Soo Kim
Journal:  Prion       Date:  2012-11-15       Impact factor: 3.931

Review 9.  Plasminogen activator inhibitor-1: the double-edged sword in apoptosis.

Authors:  Rashna D Balsara; Victoria A Ploplis
Journal:  Thromb Haemost       Date:  2008-12       Impact factor: 5.249

Review 10.  The degradation of amyloid beta as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses.

Authors:  Laura Morelli; Ramiro Llovera; Sandra Ibendahl; Eduardo M Castaño
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.